Baseline variables associated with CT-P13 treatment withdrawal
| Rheumatoid arthritis | Univariate analyses | Final multivariable model | ||
| HR | p | HR | p | |
| Gender, women versus men | 1.26 (0.73 to 2.03) | 0.4 | 1.33 (0.76 to 2.32) | 0.3 |
| Age, years | 1.01 (0.99 to 1.02) | 0.4 | 1.01 (0.99 to 1.03) | 0.3 |
| Methotrexate use, no versus yes | 2.27 (1.40 to 3.69) | 0.001 | 2.17 (1.27 to 3.68) | 0.004 |
| Patient’s global score, mm | 1.01 (1.00 to 1.02) | 0.049 | 1.01 (1.00 to 1.02) | 0.085 |
| DAS28 | 1.20 (0.99 to 1.46) | 0.06 | – | – |
| CRP, mg/L | 1.00 (0.99 to 1.02) | 0.8 | – | – |
| Longer CT-P13 interval, weeks | 0.96 (0.82 to 1.13) | 0.6 | – | – |
| Higher CT-P13 dose, mg/kg | 1.14 (0.94 to 1.38) | 0.14 | – | – |
| INX start year, 2000–2007 versus 2008–2015 | 0.83 (0.53 to 1.30) | 0.8 | – | – |
| Number of comorbidities | 1.36 (1.04 to 1.76) | 0.025 | – | – |